Ansell (ANN) H2 2024 earnings summary

Executive summary

• Adjusted EPS of US105.5¢, near the upper end of guidance, with strong cash conversion and margin expansion in the Industrial segment.

• FY24 sales declined 2.2% to $1,619.3m, with Industrial growth offsetting Healthcare contraction; GPADE margin improved 100bps to 31.9% and EBIT margin rose 20bps to 12.1%.

• KCPPE (KBU) acquisition completed July 1, enhancing presence in Scientific and Industrial markets, with integration progressing well and initial customer response positive.

• Strong H2 performance with sequential sales growth in both segments; APIP delivered $28m in savings.

• Sustainability initiatives advanced, including reduced emissions, zero waste to landfill, and top-tier ratings from EcoVadis and Sustainalytics.

Financial highlights

• Sales: $1,619.3m, down 2.2% year-over-year (constant currency -2.9%).

• EBIT: $195.5m, down 5.2% (constant currency -1.3%); EBIT margin at 12.1%.

• Adjusted EPS: US105.5¢ (-6.9%); statutory EPS: US59.4¢ (-46.3%).

• Operating cash flow: $167.9m; cash conversion at 131% due to significant working capital reduction.

• Dividend per share: US38.40¢ (payout ratio 40%).

Outlook and guidance

• FY25 Adjusted EPS guidance set at US107¢–US127¢, maintaining a wide range due to KBU integration and geopolitical risks.

• Organic constant currency sales growth anticipated in both segments as destocking effects subside.

• KBU expected to be modestly accretive to EPS in FY25, with synergies realized from FY26.

• Raw material and freight costs expected to rise moderately, with price increases to offset in H2.

• Capex planned at $60–70m, including completion of India Surgical facility.